ClinicalTrials.gg
CompletedNCT00548340Updated Oct 15, 2014Results posted

VEC-162 Study in Adult Patients With Primary Insomnia

A Phase 3 interventional study of VEC-162 20 mg and Placebo in Primary Insomnia, sponsored by Vanda Pharmaceuticals. Completed at 35 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-10-15.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 146 open to participants now, 183 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Enrollment
102nd of 855
322 · median 60
Started
2007
with 33 others
Phase 3
68 of 903
4 open now
Registered
98th of 903
by date

Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 102nd largest by enrollment of the 855 interventional ones that give a count, is one of 34 that started in 2007, is one of 68 in phase 3, and was the 98th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

146 of the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

141 more — sign in →

All 146 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.

03

Conditions studied

  • Primary Insomnia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females with a diagnosis of primary insomnia as defined in .
  • Habitual bedtime between 9:00 pm and 1:00 am.
  • No history or evidence of restless leg syndrome or periodic limb movement disorder or sleep apnea.
  • Patients must sign a written consent form.

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol abuse as defined in .
  • History of psychiatric disorders, including Major Depressive Disorder, Generalized Anxiety Disorder and delirium.
  • History of (COPD), seizures, sleep apnea, narcolepsy, circadian-rhythm sleep disorder, parasomnia or any sleep disorder other than chronic insomnia.
  • Recent history of shift work or jet lag.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    VEC-162 20 mg

    VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks

    Drug: VEC-162 20 mg

  • Experimental
    VEC-162 50 mg

    VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks

    Drug: VEC-162 50 mg

  • Placebo comparator
    Placebo

    Placebo capsules PO daily five weeks

    Drug: Placebo

Interventions

  • 20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

  • DrugPlacebo

    Placebo capsules, PO daily for five weeks

  • 50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

06

What researchers measure

Primary outcomes

  1. Average Change From Baseline - Latency to Persistent Sleep (LPS)

    Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point at which 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline and the average of nights 1 and 8.

    Time frame: Baseline, Night 1, and Night 8 measurement

Secondary outcomes

  1. Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)

    Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 1 and 8. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 1 and 8.

    Time frame: Baseline, Night 1, and Night 8 measurements for WASO and TST

07

Results

Posted Oct 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneVEC-162 20 mgVEC-162 50 mgPlacebo
Started109109104
Completed1019895
Not completed8119
Withdrew: Protocol violation233
Withdrew: Adverse event222
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject243
Withdrew: Other111

Outcome measures

PrimaryAverage Change From Baseline - Latency to Persistent Sleep (LPS)

Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point at which 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline and the average of nights 1 and 8.

Time frame:
Baseline, Night 1, and Night 8 measurement
Reported as:
Mean · minutes
Average Change From Baseline - Latency to Persistent Sleep (LPS)
minutesVEC-162 20 mgVEC-162 50 mgPlacebo
Average Change From Baseline - Latency to Persistent Sleep (LPS)45.0 ± 2.96546.4 ± 2.95428.3 ± 3.020
SecondaryAverage Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)

Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 1 and 8. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 1 and 8.

Time frame:
Baseline, Night 1, and Night 8 measurements for WASO and TST
Reported as:
Mean · minutes
Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)
minutesVEC-162 20 mgVEC-162 50 mgPlacebo
Avg WASO Change from Baseline12.2 ± 4.34914.1 ± 4.32911.7 ± 4.569
Avg TST Change from Baseline51.4 ± 4.79452.0 ± 4.77539.9 ± 4.882
Post-hocAverage Change From Baseline - Latency to Persistent Sleep (LPS)

Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline, and the average of nights 22 and 29.

Time frame:
Baseline, Night 22, and Night 29 measurement
Reported as:
Mean · minutes
Average Change From Baseline - Latency to Persistent Sleep (LPS)
minutesVEC-162 20 mgVEC-162 50 mgPlacebo
Average Change From Baseline - Latency to Persistent Sleep (LPS)49.4 ± 3.30945.1 ± 3.29233.9 ± 3.338
Post-hocAverage Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)

Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 22 and 29. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 22 and 29.

Time frame:
Baseline, Night 22, and Night 29 measurements for WASO and TST
Reported as:
Mean · minutes
Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)
minutesVEC-162 20 mgVEC-162 50 mgPlacebo
Avg WASO Change from Baseline17.7 ± 4.13910.2 ± 4.18420.3 ± 4.381
Avg TST Change from Baseline60.3 ± 4.82148.6 ± 4.80247.4 ± 4.882

Adverse events

Collected over Night 1 to Day 37 (EOS). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VEC-162 20 mg—1/109 (0.9%)15/109 (13.8%)
VEC-162 50 mg—0/109 (0%)13/109 (11.9%)
Placebo—1/104 (1%)11/109 (10.1%)
Most frequent serious events
Most frequent serious events
EventVEC-162 20 mgVEC-162 50 mgPlacebo
Hypertensive EmergencyVascular disorders0/1090/1091/104
Blood Pressure IncreasedInvestigations1/1090/1090/104
Most frequent other events
Most frequent other events
EventVEC-162 20 mgVEC-162 50 mgPlacebo
HeadacheNervous system disorders11/1094/1095/109
Blood Creatine Phosphokinase IncreasedInvestigations0/1095/1092/109
NasopharyngitisInfections and infestations3/1094/1094/109
Urinary Tract InfectionInfections and infestations4/1092/1091/109

Baseline characteristics

Age, Continuous
Age, Continuous(years)VEC-162 20 mgVEC-162 50 mgPlaceboTotal
Mean42.9 ± 10.640.7 ± 10.441.7 ± 11.841.8 ± 10.9
Age, Categorical
Age, Categorical(Participants)VEC-162 20 mgVEC-162 50 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years109109104322
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)VEC-162 20 mgVEC-162 50 mgPlaceboTotal
Female666368197
Male434636125
08

Study locations

35 sites
  • Vanda Investigational Site
    Birmingham, Alabama, United States
  • Vanda Investigational Site
    Hot Springs, Arkansas, United States
  • Vanda Investigational Site
    Little Rock, Arkansas, United States
  • Vanda Investigational Site
    Anaheim, California, United States
  • Vanda Investigational Site
    Burbank, California, United States
  • Vanda Investigational Site
    Los Angeles, California, United States
  • Vanda Investigational Site
    San Diego, California, United States
  • Vanda Investigational Site
    Santa Monica, California, United States
  • Vanda Investigational Site
    Colorado Springs, Colorado, United States
  • Vanda Investigational Site
    Hallandale Beach, Florida, United States
  • Vanda Investigational Site
    Miami, Florida, United States
  • Vanda Investigational Site
    Naples, Florida, United States
  • Vanda Investigational Site
    Orlando, Florida, United States
  • Vanda Investigational Site
    Pembroke Pines, Florida, United States
  • Vanda Investigational Site
    St. Petersburg, Florida, United States
  • Vanda Investigational Site
    Atlanta, Georgia, United States
  • Vanda Investigational Site
    Chicago, Illinois, United States
  • Vanda Investigational Site
    Overland Park, Kansas, United States
  • Vanda Investigational Site
    Crestview Hills, Kentucky, United States
  • Vanda Investigational Site
    Lexington, Kentucky, United States
  • Vanda Investigational Site
    Louisville, Kentucky, United States
  • Vanda Investigational Site
    Chevy Chase, Maryland, United States
  • Vanda Investigational Site
    Newton, Massachusetts, United States
  • Vanda Investigational Site
    Troy, Michigan, United States
  • Vanda Investigational Site
    Chesterfield, Missouri, United States
  • Vanda Investigational Site
    Las Vegas, Nevada, United States
  • Vanda Investigational Site
    New York, New York, United States
  • Vanda Investigational Site
    West Seneca, New York, United States
  • Vanda Investigational Site
    Raleigh, North Carolina, United States
  • Vanda Investigational Site
    Beachwood, Ohio, United States
  • Vanda Investigational Site
    Cincinnati, Ohio, United States
  • Vanda Investigational Site
    Oklahoma City, Oklahoma, United States
  • Vanda Investigational Site
    Columbia, South Carolina, United States
  • Vanda Investigational Site
    Austin, Texas, United States
  • Vanda Investigational Site
    Dallas, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 8 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2007
First posted
Oct 23, 2007
Start
Nov 2007
Primary completionActual
Feb 2008
CompletionActual
Jun 2008
Results delay requested
Jun 9, 2011
Results first posted
Oct 15, 2014
Last update
Oct 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00548340
Responsible party
Sponsor
First posted
Oct 23, 2007
Start date
Nov 2007
Primary completion
Feb 2008
Completion
Jun 2008
Results posted
Oct 15, 2014
Last update
Oct 15, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion